Rosén T, Johannsson G, Johansson J O, Bengtsson B A
Research Centre for Endocrinology and Metabolism, RCEM, Sahlgrenska University Hospital, Göteborg, Sweden.
Horm Res. 1995;43(1-3):93-9. doi: 10.1159/000184245.
Growth hormone deficiency (GHD) in adults is now recognized as a specific clinical syndrome with characteristic symptoms and signs. Thus, the patients are overweight, have an abnormal body composition (excess body fat and a decrease in the extracellular water volume) and a low bone mineral content compared to normals. Furthermore, the GHD patients have lipid abnormalities, decreased insulin sensitivity and a decreased fibrinolysis. Finally, the 'quality of life' is low in terms of energy and social life. Short- and long-term studies with recombinant human GH (rhGH) treatment have shown normalization of body composition, increase in the lipid pattern and marked improvement of the psychological well-being. The treatment seems safe with no serious side effects reported. In analogy with other hormonal replacement therapies, the rhGH dose should be individualized.
成人生长激素缺乏症（GHD）现在被认为是一种具有特征性症状和体征的特定临床综合征。因此，与正常人相比，这些患者体重超重，身体成分异常（体脂过多且细胞外液量减少），骨矿物质含量低。此外，GHD患者存在脂质异常、胰岛素敏感性降低和纤维蛋白溶解功能下降。最后，在能量和社会生活方面，“生活质量”较低。重组人生长激素（rhGH）治疗的短期和长期研究表明，身体成分恢复正常，脂质模式改善，心理健康显著改善。该治疗似乎是安全的，未报告严重副作用。与其他激素替代疗法类似，rhGH剂量应个体化。
